The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Novel transplant approaches in patients with AML
Justin Ching Ting Loke, BM BCh, PhD, University of Birmingham, Birmingham, UK, provides an overview of strategies to optimize allogeneic stem cell transplant in patients undergoing intensive and non-intensive treatment. Introduction of targeted therapies can reduce the intensity of transplant conditions, and minimal residual disease (MRD) monitoring can help improve patient outcomes. Additional strategies to improve transplantation outcomes include maintenance therapy, which has been investigated in the AMADEUS trial (NCT04173533), where maintenance azacitidine was assessed in patients with acute myeloid leukemia (AML). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
